Medication info
Olmedipin Tablet 10/40 mg (Amlodipine, Olmesartan)

Olmedipin Tablet 10/40 mg (Amlodipine, Olmesartan)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›13.888mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Myungjin Pharmaceutical Co., Ltd.
Appearance
Reddish-brown circular film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201502461 · Approved 2015.04.27 · Insurance code 651904190

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). Before administering this drug, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil); however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with decreased effective intravascular volume: In patients who may have decreased effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This drug should not be administered to patients with severe hepatic impairment. (See section 2, “Patients in whom this drug should not be administered,” under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and coexisting diseases. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this drug have not been established in pediatric patients younger than 18 years.

Ingredients

Manufacturer
Myungjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used to effectively lower and manage blood pressure in patients with essential hypertension who have difficulty controlling blood pressure with monotherapy of Amlodipine or Olmesartan Medoxomil.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). Before administering this drug, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil); however, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild or moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with decreased effective intravascular volume: In patients who may have decreased effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild or moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This drug should not be administered to patients with severe hepatic impairment. (See section 2, “Patients in whom this drug should not be administered,” under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient’s renal or cardiac function and coexisting diseases. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this drug have not been established in pediatric patients younger than 18 years.

Precautions

This medication may cause serious harm or death to the fetus and newborn if administered to pregnant women during the second and third trimesters. Therefore, it should be discontinued immediately upon confirmation of pregnancy. Do not administer this medication to patients who are allergic to its active ingredients or similar classes, pregnant or breastfeeding women, severe liver impairment patients, severe aortic stenosis patients, biliary obstruction patients, dialysis patients, shock state patients, and certain diabetic patients. For hypotensive patients who are deficient in fluid or salt, hypotensive symptoms may appear, so careful monitoring of their condition is necessary. Rapid vascular dilation may cause hypotension, hence caution is particularly needed for aortic stenosis patients. Patients with severe obstructive coronary artery disease or congestive heart failure should use this medication cautiously as it might affect heart function. In patients with impaired kidney function, renal function may worsen, hence, blood tests and condition should be observed carefully. In patients with liver dysfunction, metabolism of this drug may slow down, requiring caution. During the course of taking this medication, side effects such as dizziness, headache, hypotension, edema, and dyspepsia may occur, and in severe cases, consult a physician immediately. This medication should not be taken during pregnancy, and if breastfeeding, it is recommended to discontinue either breastfeeding or the medication since it can be transmitted through milk. It is not advisable to administer this medication to children under 18 years of age as safety and efficacy have not been established. In the elderly, decreased kidney and liver function may lead to increased drug concentration, so starting with a low dose and closely monitoring the condition is essential. In the case of overdose, severe hypotension, vascular dilation, and tachycardia may occur, requiring immediate medical treatment, with continuous monitoring of blood pressure and heart function. This medication should be stored away from moisture, heat, and direct sunlight, out of reach of children. When combining with other medications, consult a physician or pharmacist regarding the potential for interactions, particularly with potassium-sparing diuretics or medications that may pose a risk of hyperkalemia.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, hypoesthesia, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, upper abdominal pain, rash, urticaria, muscle tension, limb pain, back pain, polyuria, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased uric acid, increased gamma-glutamyl transferase, decreased hemoglobin and hematocrit, cholelithiasis, female breast neoplasm, exacerbation of cerebral infarction, gingival bleeding, orthostatic dizziness, chest pain, cold, increased CRP, fever, hemoptysis, excessive sneezing, rhinorrhea, laryngitis, arthritis, flank pain, generalized pain, hypoglycemia, weight loss, heartburn, gastroenteritis, shingles, diplopia, asthenia, angioedema, chronic malabsorption syndrome - similar intestinal disease, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, hair loss, itching, urticaria, autoimmune hepatitis, hyperkalemia, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, hypotension, tachycardia, bradycardia, non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air or moisture. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Reddish-brown circular film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.